Home
Cepheid

Cepheid Market Share Analysis for February 2026

Cepheid is an American molecular diagnostics company that is a wholly owned subsidiary of Danaher Corporation. Its systems automate traditional nucleic acid tests. The tests can be used to identify and analyze pathogens and genetic disorders.

Health > Biotechnology and Pharmaceuticals

Domaincepheid.com

Year Founded1996

Employees5001 - 10000

Annual Revenue> $1B

Cepheid

Cepheid (including company regionals)

cepheid.com

See more website traffic and engagement information

Cepheid Revenue up to February 2026 is > 1B

revenue generated by Cepheid top domains

Cepheid top domains revenue over 3 years

Revenue for Cepheid top domains

cepheid.com> 1B

See more with Sales Intelligence

Total visits to Cepheid's top domains

Understand Cepheid market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

cepheid.com84.9K

See more with Sales Intelligence

Avg. visit duration in Cepheid's top domains

Analyze Cepheid engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

cepheid.com00:02:27

See more with Sales Intelligence

Avg. pageviews on Cepheid's top domains

See how Cepheid keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

cepheid.com2.81

See more with Sales Intelligence

Cepheid top competitors by domain

Top similar sites in February 2026, ranked by their affinity

danaher.comCompany NameDanaherEmployees> 10001HQUnited States, District of Columbia, Washington, D.C.Annual revenue> $1BTotal visits302.4KFinance > Finance - Other

Top technologies used by Cepheid

These are the website technologies, by industry, used by Cepheid top domains

Advertising (24)

Google Adsense

Payment & Currencies (22)

Cart Functionality

Conversion & Analytics (13)

Google Analytics

Marketing (9)

Google Marketing Platform

More Technologies

13

See all

News & Signals from Cepheid

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsCepheid Inc signs new client CDC.Cepheid has been chosen by the CDC as a national collaborator to fast-track the development and deployment of rapid diagnostic tests during health emergencies, leveraging early access to outbreak data and samples.

NewsCepheid Inc launches point-of-care PCR test for SARS-CoV-2 in the United States.Cepheid's legacy of rapid assay development was exemplified during the COVID-19 pandemic, when the company launched the first point-of-care PCR test for SARS-CoV-2 in the United States[2] within weeks of the viral sequence being published.

NewsCepheid Inc partners with Rutgers University.Cepheid continued to invest in improving TB diagnostics in collaboration with FIND and Rutgers New Jersey Medical School starting in 2014.[4] The resulting second-generation test, Xpert MTB/RIF Ultra, was released in 2017, followed by Xpert MTB/XDR in 2020.